Clinical Trial Update: A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating belzutifan plus pembrolizumab versus placebo plus pembrolizumab in post-nephrectomy clear cell renal cell carcinoma; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Belzutifan (belzutifan)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING